AI Article Synopsis
Article Abstract
Seven patients age 80-106 who presented with signs and symptoms of depression were successfully treated with 1.25-10 mg of methylphenidate per day without evidence of toxicity or tolerance. Treatment was continued for up to 24 months with sustained benefits.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00019442-199300120-00011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prescribing Psychostimulants for the Treatment of Stimulant Use Disorder: Navigating the Federal Legal Landscape.
J Addict Med
January 2025
From the Division of General Internal Medicine, San Francisco General Hospital, Department of Medicine, University of California San Francisco, San Francisco, CA (LWS); San Francisco Department of Public Health, San Francisco, CA (POC); Vital Strategies, New York, NY (KB, DC); Network for Public Health Law, Edina, MN (CSD); and New York University Grossman School of Medicine, New York, NY (CSD).
Stimulant use disorder (StUD) is a rapidly growing concern in the United States, with escalating rates of death attributed to amphetamines and cocaine. No medications are currently approved for StUD treatment, leaving clinicians to navigate off-label medication options. Recent studies suggest that controlled prescription psychostimulants such as dextroamphetamine, methylphenidate, and modafinil are associated with reductions in self-reported stimulant use, craving, and depressive symptoms.
View Article and Find Full Text PDFPathogenesis-directed therapy of methylphenidate-induced oxidative heart damage in rats.
Front Pharmacol
January 2025
Department of Pharmacology, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Türkiye.
Aim: The current study aimed to investigate the protective effects of adenosine triphosphate (ATP), metyrosine, and melatonin on possible methylphenidate cardiotoxicity in rats using biochemical and histopathological methods.
Methods: Thirty rats were separated into five groups: healthy (HG), methylphenidate (MP), ATP + methylphenidate (ATMP), metyrosine + methylphenidate (MSMP), and melatonin + methylphenidate (MLMP). ATP (5 mg/kg) was given intraperitoneally once daily, metyrosine (50 mg/kg) orally twice daily, and melatonin (10 mg/kg) orally once daily.
Metoclopramide-induced rapid-onset psychosis in a child with methylphenidate use: a case report.
Turk J Pediatr
December 2024
Department of Pediatric Neurology, Ankara Bilkent City Hospital, Ankara Yildirim Beyazit University Faculty of Medicine, Ankara, Türkiye.
Background: Metoclopramide, a dopamine antagonist employed for its antiemetic effects, can precipitate neuropsychiatric adverse effects, including extrapyramidal symptoms and, in a few instances, acute psychosis. Although there have been reports of metoclopramide-induced psychosis in elderly individuals, there is no documentation of such incidents in children as far as we are aware.
Case Presentation: This case report describes an 11-year-old girl with a history of mild intellectual disability and attention deficit hyperactivity disorder, managed with 10 mg of methylphenidate daily.
Prevalence and Temporal Trends of Attention Deficit Hyperactivity Disorder Medication Fills During Pregnancy and Breastfeeding in Denmark.
Paediatr Drugs
January 2025
National Centre for Register-based Research, Aarhus University, Fuglesangs Allé 26, 8210, Aarhus V, Denmark.
Background And Objectives: Females of reproductive age are increasingly using attention deficit hyperactivity disorder (ADHD) medication, but its use during pregnancy and breastfeeding is largely unknown. The aim of this study is to examine the prevalence of ADHD medication fills during pregnancy and breastfeeding, including characteristics of these females and cohort differences over time.
Methods: We conducted a descriptive study using Danish nationwide registers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!